Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Other Accumulated Expenses (2021 - 2026)

Oramed Pharmaceuticals filings provide 5 years of Other Accumulated Expenses readings, the most recent being $1.7 million for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 24.6% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 24.6% year-over-year, with the annual reading at $1.7 million for FY2025, 24.6% up from the prior year.
  • Other Accumulated Expenses hit $1.7 million in Q4 2025 for Oramed Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.7 million in Q4 2025 and bottomed at $243.0 in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $328172.5, with a median of $133000.0 recorded in 2022.
  • The largest annual shift saw Other Accumulated Expenses crashed 55.64% in 2023 before it soared 2228.81% in 2024.
  • Oramed Pharmaceuticals' Other Accumulated Expenses stood at $207000.0 in 2021, then plummeted by 35.75% to $133000.0 in 2022, then tumbled by 55.64% to $59000.0 in 2023, then soared by 2228.81% to $1.4 million in 2024, then rose by 24.6% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Other Accumulated Expenses are $1.7 million (Q4 2025), $1.4 million (Q4 2024), and $59000.0 (Q1 2024).